Thymic
carcinoma, also known as thymomas, is a rare type of cancer that forms
in the cells present in the outside surface of the thymus. Thymus is a small
organ that lies in the upper chest under the breastbone.
It is a part of the lymph system and produces certain types
of white blood cells that helps the body to fight against infections. The tumor
cells in a thymoma look like the normal cells of the thymus which grow slowly
and rarely spread beyond the thymus.
Request to Get the Sample Pages at:
The drug candidates of thymic carcinoma disease pipeline
include, but not limited to, pembrolizumab, and milciclib maleate. Some of the
companies having drugs in the thymic carcinoma disease pipeline includes Merck
& Co. Inc., NMS Group SpA and Tiziana Life Sciences plc.
The report provides a comprehensive understanding of the
pipeline activities covering all drug candidates under various stages of
development, with the detailed analysis of pipeline and clinical trials.
Pipeline analysis of drugs by phases includes product
description and development activities including information about clinical
results, designations, collaborations, licensing, grants, technology, and
others.
No comments:
Post a Comment